Tag: Intellectual Property
-
Call for Consultant: Acceptance Study of New Generation Long-Acting ARVs Among PLWHIV in the MENA Region
Terms of Reference (ToR) for ConsultationDemand Creation for New Generation ARVs – Acceptance Study Among PLWHIV 1. Context and Justification The Middle East and North Africa (MENA) region faces a growing HIV epidemic, characterized by increasing uncertainties regarding its incidence and consequences. Data indicate that AIDS-related deaths surged by 66% between 2005 and 2013, emphasizing…
-
Results of a study on lenacapavir and two broadly neutralizing antibodies were presented at CROI 2025.
At the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, results were presented from a Phase II study examining the efficacy of a combination of lenacapavir (TN Sunlenca) and two broadly neutralizing antibodies (bNAbs) – teropavimab and zinlirvimab. The study results indicate that this regimen could form the basis of a complete…
-
Call for Talents: Transform the Fight against HIV with ADP-MENA (Activists Development Program in MENA Region)
Context: The Middle East and North Africa (MENA) region continues to face major public health challenges related to HIV/AIDS. Key populations, including young people, men who have sex with men, sex workers, and injecting drug users, face significant barriers to accessing prevention and treatment services. These obstacles are exacerbated by stigma, discrimination, and a lack…
-
TERMS OF REFERENCE FOR AUDIOVISUAL AGENCY FOR GLOBAL SUMMIT 2025
ABOUT ITPC-MENA ITPC-MENA is a regional non-governmental organization operating in the MiddleEast and North Africa region bringing together a network of community activistsunited by our vision of a longer, healthier, more productive life for people living withHIV and/or HCV. ITPC-MENA’s mission is to enable communities in need, to accessHIV, HCV and TB treatment. ITPC-MENA was formed…
-
Call for Applications for the ADP (Activist Development Program) on HIV and Leadership Training in MENA Region
*Focus only on (Egypt, Lebanon, Morocco, Jordan, and Tunisia). ITPC-MENA is delighted to announce the launch of our HIV and Leadership training program designed for young activists. This program is crafted to enhance the capacities of young activists to become leaders in the fight against HIV and AIDS. HIV is a disease that affects millions…
-
ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-INCOME COUNTRIES: A REAL RACE IS STARTING AMONG PHARMACEUTICAL COMPANIES FOR MARKET SHARE AND PROFIT
Source : ITPC EECA Against the backdrop of a recent press release from Gilead announcing the signing of a voluntary license for the new drug lenacapavir, ViiV Healthcare has announced an increase in the supply of its injectable drug cabotegravir. This sequence of events inevitably raises the thought that a real race is starting among…
-
“Not in Our Name” – African HIV Treatment Advocates React to Gilead’s Voluntary Licensing Agreement on Lenacapavir
Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant concerns despite the inclusion of most African countries in the license territory. Exclusionary Practices: While most countries of the continent are part of…
-
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essential Medicines
Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies to deliver genuine global access strategies for the medicines, vaccines and diagnostics that the world needs. Lenacapavir (LEN), a twice-yearly injection, has…
-
MENACAB 2021 – 2022 REPORT : TREATMENT ACCESS IN TIME OF PANDEMICS
Since the beginning of the HIV epidemic, Community Advisory Boards (CABs) constituted an effective tool to link communities as real partners with researchers and drug manufacturers; educate people living with HIV and their advocates, disseminate information about research and drug development, and to discuss access strategies. The first meeting of MENACAB took place in 2014.…
-
Othmane MARRAKCHI: ITPC-MENA’s new Advocacy Officer.
ITPC-MENA is pleased to inform you that Mr. Othmane MARRAKCHI has recently joined ITPC-MENA as Advocacy Officer for Access to Medicines. In this position, Mr. Othmane MARRAKCHI will manage the development and implementation of the ITPC-MENA project on the use of TRIPS1 flexibilities to enable access to HIV, HCV, and tuberculosis treatments in developing countries.…